Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis

This study is to evaluate the efficacy and safety of DA-5219 in patients with acute or chronic gastritis

Main Inclusion Criteria:

• Men or women aged ≥ 19 years and ≤ 75 years
• Subjects who diagnosed with acute or chronic gastritis by upper gastrointestinal endoscopy within 7days prior to the randomization
• Subjects who have one or more erosions identified on upper gastrointestinal endoscopy within 7days prior to the randomization
• Subjects who voluntarily signed a consent form

Main Exclusion Criteria:

• Ineligible for upper gastrointestinal endoscopy
• Subjects with active or healing gastroduodenal ulcer, reflux esophagitis, Barrett's esophagus, or gastroesophageal varices identified on upper gastrointestinal endoscopy within 7days prior to the randomization
• Subjects with hypersensitivity to investigational drugs and similar drugs
• Pregnant or breastfeeding women